Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Monday that it has entered into a definitive agreement to acquire Intra-Cellular Therapies Inc (Nasdaq:ITCI), a biopharmaceutical company focused on central nervous system (CNS) disorders, for USD132.00 per share in cash.
The acquisition includes CAPLYTA (lumateperone), approved for the treatment of schizophrenia and bipolar depression. The US Food and Drug Administration (FDA) is currently reviewing an application for CAPLYTA as an adjunctive treatment for major depressive disorder (MDD).
CAPLYTA has the potential to become a standard of care for most common depressive disorders and is expected to generate USD5bn+ in peak year sales. The deal also includes ITI-1284, a promising Phase 2 compound being studied in generalised anxiety disorder and Alzheimer's disease-related psychosis and agitation.
Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close later this year.
Karyopharm seeks accelerated FDA approval for selinexor–ruxolitinib in myelofibrosis
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
Zambon receives European Commission approval for Hopledo in Parkinson's disease
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
Annovis Bio schedules corporate update webinar for next week
Cellenkos' CK0803 granted US FDA Fast Track designation for ALS
Labcorp to offer FDA-cleared pTau-217 blood test for Alzheimer's assessment
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Vanda's imsidolimab
United Therapeutics wins FDA acceptance for ralinepag PAH filing
Acadia wins EU approval for DAYBU as first treatment for Rett syndrome